Inactivation of MyoD-mediated expression of p21 in tumor cell lines

Cell Growth and Differentiation

Volumn 8, Issue 11, 1997, Pages 1151-1160

  Otten, Anne D ^a   Firpo, Eduardo J ^a   Gerber, Anthony N ^a   Brody, Linnea L ^a   Roberts, James M ^a   Tapscott, Stephen J ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DNA; HELIX LOOP HELIX PROTEIN; PROTEIN P21;

ARTICLE; CELL TRANSFORMATION; DNA CONTENT; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; STRUCTURAL GENE;

ANIMALS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; HELIX-LOOP-HELIX MOTIFS; HUMANS; MYOD PROTEIN; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030778399     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Hinds, P. W., and Weinberg, R. A. Tumor suppressor genes. Curr. Opin. Genet. Dev., 4: 135-141, 1994.
2. Paggi, M. G., Baldi, A., Bonetto, F., and Giordano, A. Retinoblastoma protein family in cell cycle and cancer: a review. J. Cell. Biochem., 62; 418-430, 1996.
3. INK4 genes in hematologic malignancies. Leuk. Lymphoma, 23: 235-245, 1996.
4. Cox, L. A., Chen, G., and Lee, E. Y. Tumor suppressor genes and their roles in breast cancer. Breast Cancer Res. Treat., 32: 19-38, 1994.
5. Jarman, A. P., Brand, Wl., Jan, L. Y., and Jan, Y. N. The regulation and function of the helix-loop-helix gene, asense, in Drosophila neural precursors. Development (Camb.), 119: 19-29, 1993.
6. Rudnicki, M. A., Schnegelsberg, P. N., Stead, R. H., Braun, T., Arnold, H. H., and Jaenisch, R. MyoD or Myf-5 is required for the formation of skeletal muscle. Cell, 75: 1351-1359, 1993.
7. Zhuang, Y., Soriano, P., and Weintraub, H. The helix-loop-helix gene E2A is required for B cell formation. Cell, 79: 875-884, 1994.
8. Giangrande, A. Proneural genes influence gliogenesis in Drosophila. Development (Camb.), 121: 429-438, 1995.
9. Lee, J. E., Hollenberg, S. M., Snider, L., Turner, D. L., Lipnick, N, and Weintraub, H. Conversion of Xenopus ectoderm into neurons by NeuroD, a basic helix-loop-helix protein. Science (Washington DC), 268; 836-844, 1995.
10. Guillemot, F. Analysis of the rale of basic helix-loop-helix transcription factors in the development of neural lineages in the mouse. Biol. Cell, 84: 3-6, 1995.
11. Blanar, M. A., Crossley, P. H., Peters, K. G., Steingrimsson, E., Copeland, N. G., Jenkins, N. A., Martin, G. R., and Rutter, W. J. Meso1, a basic helix-loop-helix protein involved in mammalian presomitic mesoderm development. Proc. Natl. Acad. Sci. USA, 92: 5870-5874, 1995.
12. Cserjesi, P., Brown, D., Ligon, K. L., Lyons, G. E., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., and Olson, E. N. Scleraxis: a basic helix-loop-helix protein that prefigures skeletal formation during mouse embry-ogenesis. Development (Camb.), 121: 1099-1110, 1995.
13. Braun, T., and Arnold, H. H. Myf-5 and myoD genes are activated in distinct mesenchymal stem cells and determine different skeletal muscle cell lineages. EMBO J., 15: 310-318, 1996.
14. Tonin, P. N., Scrable, H., Shimada, H., and Cavenee, W. K. Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res., 51: 5100-5106, 1991.
15. Tapscott, S. J., Thayer, M. J., and Weintraub, H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science (Washington DC), 259; 1450-1453, 1993.
16. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69; 1237-1245, 1992.
17. Fiddler, T. A., Smith, L., Tapscott, S. J., and Thayer, M. J. Amplification of MDM2 inhibits MyoD-mediated myogenesis. Mol. Cell. Biol., 16: 5048-5057, 1996.
18. Davis, R. L, Weintraub, H., and Lassar, A. B. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell, 51: 987-1000, 1987.
19. Weintraub, H., Tapscott, S. J., Davis, R. L., Thayer, M. J., Adam, M. A., Lassar, A. B., and Miller, A. D. Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. Proc. Natl. Acad. Sci. USA, 86: 5434-5438, 1989.
20. Sancho, S., Mongini, T., Tanji, K., Tapscott, S. J., Walker, W. F., Weintraub, H., Miller, A. D., and Miranda, A. F. Analysis of dystrophin expression after activation of myogenesis in amniocytes, chorionic-villus cells, and fibroblasts. A new method for diagnosing Duchenne's muscular dystrophy. N. Engl. J. Med., 329: 915-920, 1993.
21. Choi, J., Costa, M. L., Mermelstein, C. S., Chagas, C., Holtzer, S., and Holtzer, H. MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes. Proc. Natl. Acad. Sci. USA, 87: 7988-7992, 1990.
22. Gerber, A. N., and Tapscott, S. J. Tumor cell complementation groups based on myogenic potential: evidence for inactivation of loci required for basic helix-loop-helix protein activity. Mol. Cell. Biol., 76: 3901-3908, 1996.
23. Sorrentino, V., Pepperkok, R., Davis, R. L., Ansorge, W., and Philipson, L. Cell proliferation inhibited by MyoD1 independently of myogenic differentiation. Nature (Lond.), 345: 813-815, 1990.
24. Crescenzi, M., Fleming, T. P., Lassar, A. B., Weintraub, H., and Aaronson, S. A. MyoD induces growth arrest independent of differentiation in normal and transformed cells. Proc. Natl. Acad. Sci. USA, 87: 8442-8446, 1990.
25. Thorburn, A. M., Walton, P. A., and Feramisco, J. R. MyoD-induced cell cycle arrest is associated with increased nuclear affinity of the Rb protein. Mol. Biol. Cell, 4: 705-713, 1993.
26. Coppola, J. A., Lewis, B. A., and Cole, M. D. Increased retinoblastoma gene expression is associated with late stages of differentiation in many different cell types. Oncogene, 5: 1731-1733, 1990.
27. Martelli, F., Cenciarelli, C., Santarelli, G., Polikar, B., Felsani, A., and Caruso, M. MyoD induces retinoblastoma gene expression during myogenic differentiation. Oncogene, 9: 3579-3590, 1994.
28. Gu, W., Schneider, J. W., Condorelli, G., Kaushal, S., Mahdavi, V., and Nadal-Ginard, B. Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell, 72: 309-324, 1993.
29. 1 cyclins. Cell, 73: 1059-1065, 1993.
30. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
31. Harper, J. W., Elledge, S. J., Keyomarsi, K., Dynlacht, B., Tsai, L. H., Zhang, P., Dobrowolski, S., Bai. C., Connell-Crowley, L., Swindell, E., Fox, M. P., and Wei, N. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell, 6: 387-400, 1995.
32. 1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
33. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
34. Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., and Smith, J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res., 277: 90-98, 1994.
35. Gu, Y., Turck, C. W., and Morgan, D. O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature (Lond.), 366: 707-710, 1993.
36. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor β and contact inhibition to cell cycle arrest. Genes Dev., 8: 9-22, 1994.
37. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
38. 1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
39. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev., 9: 639-649, 1995.
40. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
41. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond.), 377: 257-261, 1994.
42. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev., 8: 2939-2952, 1994.
43. ink4. Mol. Cell. Biol., 15: 2682-2688, 1995.
44. 1 arrest. Cell, 76: 1013-1023, 1994.
45. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
46. Halevy, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G. J., Beach, D., and Lassar, A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (Washington DC), 267: 1018-1021, 1995.
47. Cip1 in muscle and other terminally differentiating cells. Science (Washington DC), 267: 1024-1027, 1995.
48. Mulligan, L. M., Matlashewski, G. J., Scrable, H. J., and Cavenee, W. K. Mechanisms of p53 loss in human sarcomas. Proc. Natl. Acad. Sci. USA, 87: 5863-5867, 1990.
49. Felix, C. A., Kappel, C. C., Mitsudomi, T., Nau, M. M., Tsokos, M., Crouch, G. D., Nisen, P. D., Winick, N.J., and Helman, L. J. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res., 52: 2243-2247, 1992.
50. Hollenberg, S. M., Cheng, P. F., and Weintraub, H. Use of a conditional MyoD transcription factor in studies of MyoD trans-activation and muscle determination. Proc. Natl. Acad. Sci. USA, 90: 8028-8032, 1993.
51. Hasty, P., Bradley, A., Morris, J. H., Edmondson, D. G., Venuti, J. M., Olson, E. N., and Klein, W. H. Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. Nature (Lond.), 364: 501-506, 1993.
52. 1 checkpoint control. Cell, 82: 675-684, 1995.
53. Hollstein, M., Shomer, B., Greenblatt, M., Soussi, T., Hovig, E., Montesano, R., and Harris, C. C. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res., 24: 141-146, 1996.
54. Zhang, H., Hannon, G. J., and Beach, D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev., 8: 1750-1758, 1994.
55. Xiong, Y., Zhang, H., and Beach, D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev., 7: 1572-1583, 1993.
56. Weintraub, H., Hauschka, S., and Tapscott, S. J. The MCK enhancer contains a p53-responsive element. Proc. Natl. Acad. Sci. USA, 88: 4570-4571, 1991.
57. Soddu, S., Blandino, G., Scardigli, R., Coen, S., Marchetti, A., Rizzo, M. G., Bossi, G., Cimino, L, Crescenzi, M., and Sacchi, A. Interference with p53 inhibits hematopoietic and muscle differentiation. J. Cell Biol., 134: 193-204, 1996.
58. Shapiro, D. N., Houghton, P. J., Hazelton, B. J., Germain, G. S., Murti, K. G., Rahman, A., and Houghton, J. A. Morphological and molecular characterization of spontaneous myogenic differentiation in a human rhabdomyosarcoma cell line. Cancer Res., 50: 6002-6009, 1990.
59. Rostomily, R. C., Bermingham-McDonogh, O., Berger, M. S., Tapscott, S. J., Reh, T. A., and Olson, J. M. Expression of neurogenic bHLH genes in primitive neuroectodermal tumors. Cancer Res., 57: 3526-3531, 1997.
60. Flores-Rozas, H., Kelman, Z., Dean, F. B., Pan, Z. Q., Harper, J. W., Elledge, S. J., O'Donnell, M., and Hurwitz, J. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase 8 holoenzyme. Proc. Natl. Acad. Sci. USA, 97: 8655-8659, 1994.
61. Waga, S., Hannon, G. J., Beach, D., and Stillman, B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond.), 369: 574-578, 1994.
62. Li, R., Waga, S., Hannon, G. J., Beach, D., and Stillman, B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature (Lond.), 377: 534-537, 1994.
63. Shivji, M. K., Grey, S. J., Strausfeld, U. P., Wood, R. D., and Blow, J. J. Cip1 inhibits DNA replication but not PCNA-dependent nucleotide excision repair. Curr. Biol., 4: 1062-1068, 1994.
64. Skapek, S. X., Rhee, J., Spicer, D. B., and Lassar, A. B. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science (Washington DC), 267: 1022-1024, 1995.
65. Shiohara, M., el-Deiry, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D. L., Vogelstein, B., and Koeffler, H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781-3784, 1994.
66. Collins, M. K., and Lopez Rivas, A. The control of apoptosis in mammalian cells. Trends Biochem. Sci., 18: 307-309, 1993.
67. Wang, J., and Walsh, K. Resistance to apoptosis conferred by CDK inhibitors during myocyte differentiation. Science (Washington DC), 273: 359-361, 1996.
68. Miller, A. D., and Rosman, G. J. Improved retroviral vectors for gene transfer and expression. Biotechniques, 7: 980-982, 984-986, 989-990, 1989.
69. Davis, R. L., Cheng, P. F., Lassar, A. B., and Weintraub, H. The MyoD DNA binding domain contains a recognition code for muscle-specific gene activation. Cell, 60: 733-746, 1990.
70. Turner, D. L., and Weintraub, H. Expression of achaete-scute homolog 3 in Xenopus embryos converts ectodermal cells to a neural fate. Genes Dev., 8: 1434-1447, 1994.
71. Rupp, R. A., Snider, L., and Weintraub, H. Xenopus embryos regulate the nuclear localization of XMyoD. Genes Dev., 8: 1311-1323, 1994.
72. van den Heuvel, S., and Harlow, E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science (Washington DC), 262: 2050-2054, 1993.
73. Samuels, H. H., Stanley, F., and Casanova, J. Depletion of L-3,5,3′-triiodothyronine and L-thyroxine in euthyroid calf serum for use in cell culture studies of the action of thyroid hormone. Endocrinology, 105: 80-85, 1979.
74. Auffray, C., and Rougeon, F. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur. J. Biochem., 707: 303-314, 1980.
75. Firpo, E. J., Koff, A., Solomon, M. J., and Roberts, J. M. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol. Cell. Biol., 14: 4889-4901, 1994.
76. Marraccino, R. L., Firpo, E. J., and Roberts, J. M. Activation of the p34 CDC2 protein kinase at the start of S phase in the human cell cycle. Mol. Biol. Cell, 3: 389-401, 1992.
77. Ishioka, C., Frebourg, T., Yan, Y. X., Vidal, M., Friend, S. H., Schmidt, S., and Iggo, R. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat. Genet., 5: 124-129, 1993.
78. Flaman, J. M., Frebourg, T., Moreau, V., Charbonnier, F., Martin, C., Chappuis, P., Sappino, A. P., Limacher, I. M., Bron, L., Benhattar, J., Tada, M., Van Meir, E. G., Estreicher, A., and Iggo, R. D. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl. Acad. Sci. USA, 92: 3963-3967, 1995.
79. Vindelov, L. L., Christensen, I. J., and Nissen, N. I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry, 3: 323-327, 1983.